CommercialCoverageMedium impact
08.01.32o, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Coverage and medical necessity criteria have been updated for several cancer support medications including Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and their biosimilars. This affects reimbursement requirements for these specialized injectable drugs used to prevent infection in cancer patients receiving chemotherapy.
Action Required
Before January 1, 2026: Billing team must review and update prior authorization and documentation requirements for Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and related biosimilars in billing system. Oncology providers must ensure medical necessity documentation meets new criteria for these cancer support medications to avoid claim denials.